Background-Guidelines for heart failure (HF) recommend prescription of guideline-directed
Introduction
Initiation and continuation of individual guideline-directed medical therapies prior to hospital discharge has been associated with improved adherence and clinical outcomes for patients with heart failure (HF). [1] [2] [3] Reflective of these data, current clinical practice guidelines and hospital quality measures for HF include the following medications at discharge: 1) angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for HF with reduced ejection fraction (HFrEF), 2) beta-blocker (BB) for HFrEF, 3) aldosterone antagonists (AldA)
for HFrEF, 4) hydralazine with isosorbide dinitrate (H/ISDN) for HFrEF among AfricanAmerican patients, and 5) anticoagulants for those with atrial fibrillation. 4, 5 Quality measures are increasingly tied to hospital recognition, public reporting, and payments. 6 The vast majority of evidence for HF-related medical therapy derives from serial studies in which single medications were added to stable existing medical regimens, typically in an order dictated by scientific discovery rather than practical or physiological considerations. In the process of compiling this fragmented evidence, guidelines and quality measures in effect recommend that all of these medications be prescribed by the time of hospital discharge.
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optimal timing and sequencing for such initiation. Therefore, we set out to quantify the difference between the actual medication regimen at the time of admission and the recommended medication regimen at the time of discharge according to HF guidelines and quality measures, after accounting for documented contraindications/intolerance to such therapy.
Methods

Data Source
We conducted a cross-sectional study using data from the Get With The Guidelines®-Heart
Failure (GWTG-HF) voluntary quality improvement initiative. The design and validity of this program's methods and data capture have been published previously. Portability and Accountability Act and a random hospital identifier is used to identify the various hospitals. All participating institutions were required to comply with local regulatory and privacy guidelines and to secure institutional review board approval. Because data are used primarily at program's methods and data capture have been published previously. [9] [10] [11] Briefly, tr tr trai ai aine ne ned d d personnel at each site abstract clinical data for all patients admitted with HF in compliance with
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Medication Quality Measures
The GWTG-HF data collection form includes detailed capture of admission medications, documentation of LVEF, discharge medications, and contraindications to evidence-based therapies. Medication quality metrics defined by GWTG-HF during the study period were the following: 1) ACEI or ARB for LVEF <40%, 2) BB for LVEF <40%, 3) AldA for LVEF <35%, Multivariable logistic regression was used to identify factors associated with increased or decreased odds of a patient getting a recommended medication prescribed at discharge among the patients who were eligible and not treated prior to discharge. Among the 5 potential options, each medication class was considered as an opportunity such that a patient could have as many as 5 responses or as few as one response: one for each newly recommended medication. The
Statistical Analysis
We calculated the difference between the patient's medication regimen at the time of admission
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Other categorical variables with missing observations (all <5% missing) were imputed to the most common category. Body mass index and laboratory values at admission had more than 20% missing so were not included in modeling. Other continuous variables with missing observations were imputed to the medians. A p value 0.05 was considered statistically significant for all tests. All analyses were performed with SAS software version 9.2 (SAS Institute, Cary, NC).
Results
Hospital and Patient Characteristics
The final study sample included 158,922 patients from 271 hospitals discharged between April 1, 2008 and June 30, 2013. Among the patients eligible for at least one new medication, median age was 73 years, 60% were Caucasian, comorbidities were present in the majority of patients, and median length of stay was 4 days ( Table 1 were not eligible for any medications recommended by HF quality measures (99.0% of whom did not have reduced LVEF) ( Table 3 ). The number of patients prescribed a medication at admission and discharged without the prescription was small, ranging from 0.68% for BB to 1.58% for anticoagulants.
Recommended Medication Initiation Burden
Common Combinations of Newly Recommended and Prescribed Medications
The 5 most common combinations of newly recommended medications at discharge were anticoagulant only (23.5%), ACE/ARB+BB+AldA (12.0%), AldA only (6.1%), ACE/ARB+BB+AldA+H/ISDN (4.6%), and ACE/ARB+BB (4.4%). The combinations of medications that were newly prescribed paralleled the recommendations, albeit at lower frequencies.
New Medication Recommendations by Patient Subgroups
Among patients who were eligible for at least one new medication at discharge (N=97,888), 21 .4% had no prior diagnosis of HF, 69.8% had LVEF <40%, and 55.6% had an ischemic etiology for HF. Patients without a prior HF diagnosis had a higher number of recommended medications to initiate compared with those with a prior HF diagnosis (mean 1.7±1.3 versus did not have reduced LVEF) ( Table 3 ). The number of patients prescribed a med d dic ic icat at atio io ion n n at at at admission and discharged without the prescription was small, ranging from 0.68% for BB to 1.58 8% % % fo fo for r r an an anti t t co o oag ag agulants. of ischemic heart disease had a higher number of newly recommended medications to start compared to those with ischemic heart disease (mean 1.56±1.27 versus 1.29±1.16).
Prescribing of Newly Recommended Medications
Compared with the number of new medications indicated (mean 1.45±1.23), the number of actual new prescriptions at discharge was lower (mean 1.16±1.00). ACEI/ARB was prescribed in 91.2% of those eligible but not receiving it prior to admission, BB prescribed in 94.1%, AldA in 27.2%, H/ISDN in 18.9%, and anticoagulant in 56.4%. In multivariable analysis, a prescription at discharge for the newly recommended medications was associated with the following patient characteristics: younger age, male, Caucasian, Medicare and non-Medicaid insured; history of hyperlipidemia, implantable cardioverter-defibrillator, or renal insufficiency; absent history of PVD, anemia, pacemaker, dialysis, depression, ischemic heart disease, and smoking; absence of reduced LVEF; and higher heart rate ( Table 4) .
Discussion
Among patients hospitalized with HF, 47% needed to start at least one new HF-related medication by discharge, 24% needed to start more than one, and 14% needed to start 3 or more in order to be in compliance with current HF guidelines and quality measures. These numbers do not include additional medications indicated for non-HF comorbidities. This provides the first large description of how layering evidence-based guideline recommendations can cumulatively lead to a high number of newly recommended medications for patients discharged after worsening HF. Other studies, including analyses from GWTG-HF, have assessed overall at discharge for the newly recommended medications was associated with the foll ll low ow owin in ing g g pa pa pati ti tien en ent characteristics: younger age, male, Caucasian, Medicare and non-Medicaid insured; history of hype pe perl rl rlip ip ipid id idem em emia, im im implantable cardioverter-defibri ri ill ll llat at ator, or renal insuffic cie ie ienc n n y; absent history of P P PVD D, D anemia, p p pac ac a em em mak ak aker er er, , , d di dial al aly ys ysis is is, de de dep pr pressi si sion on n, isch ch hem m mic ic ic h h hea ea eart r r d d dis i i ea ea ease se se, an nd sm sm smok ok okin in ing; g; g a a ab b bsen en ence ce ce o o of e edu du duce c c d LV VEF EF EF; an an and hi i igh h her h h hea ea eart r r rat at ate e e (Ta Ta Table e indications for and prescribing of HF medications but have not distinguished between preexisting and new use of these medications nor have they provided an assessment of total medication initiation burden. 13, 14 As quality measures are increasingly used in public reporting and payment decisions, 6 evaluation of the cumulative burden created by process measures is crucial. While discrete recommendations may make sense in isolation, the simultaneous effect of multiple measures on patient well-being and care delivery should be factored into the overall design of reform efforts.
Research into the relative benefit of mass initiation of medications prior to discharge versus sequential initiation that extends into the ambulatory setting is needed. Staged medication initiation could be less overwhelming to patients in the difficult transition period and reduce the risk of hypotension and other side effects. Additionally, simultaneous addition of ACEI/ARB and AldA, which both have effects on kidney function and potassium handling, has not been well studied; fears of renal dysfunction and hyperkalemia may explain some of the underuse of AldA.
However, these concerns must be balanced against research showing that inpatient initiation of individual medications is relatively safe and leads to higher use of these life-prolonging medications in the long-term. 3, 15, 16 With current recommendations for 1-week post-discharge follow-up and increased attention on the transitional care period, the opportunity for sequential addition of medications exists 4, 17 If staged initiation is considered to be preferable, the order in which these medications should be started in various populations is relatively unknown and also deserves further research.
As expected from the linkage between reduced LVEF and indications for many neurohormonal-antagonist therapies, patients with HFrEF had a relatively higher burden of recommended medications to initiate compared to patients with preserved LVEF. With the nitiation could be less overwhelming to patients in the difficult transition period a a and nd nd r r red ed educ uc uce e e th th the isk of hypotension and other side effects. Additionally, simultaneous addition of ACEI/ARB and Al Al AldA dA dA, , , wh wh which h h bo b b th have effects on kidney fu u unc nc ncti ti tion and potassium h h han an ndling, has not been wel t t tud d died; fears o o of f f re ena a al l l dy y dysf sf sfun un unct ct ctio io ion n n a an and d d h hype e erk rk rkalem mi i ia m m may ay ay e e exp xp xpla ain in in s s som om ome e e o of the he he u u und nd nder er erus us use e e of f f A A Ald ld ldA. A A Ho Ho Howe we wever, the he hese s c c co on o ce ern rn rns mu u ust t t b b be ba ba bala anc nc nced a a ag ga gains st r res s sea a arch h h s s sho ho owi wi wing ng ng th h hat t in n npa pa pati t t ent t t in n nitia ati i ion o o of f n n ndi di divi i vidu d dual al al m m med ed edic ic icat at atio io ions ns ns i i is s s re re rela la lati ti tive e vely l ly s s saf af afe e e an an and d d le le lead ad ads s s to to to h h hig ig ighe he her r r us s use e e of of of t t the he hese se se l l lif if ife e e-pr pr prol ol olon on ongi gi ging ng ng common co-occurrence of HF and atrial fibrillation, HF medications and anticoagulation were also frequently co-recommended. Thus, certain patient populations, including those with multimorbidity, are likely to be disproportionately affected by this layering of guideline recommendations and quality measures, and may warrant special attention.
Medication adherence research has focused primarily on continuation of medications;
however, additions to medication regimens are typically more challenging for patients. 18 Rates of primary nonadherence (i.e. never filling a medication) often exceed the rate of medication discontinuation. 19, 20 Thus, optimizing the process for getting patients onto medications in the first place may be one of the most critical aspects of adherence interventions. [21] [22] [23] Therefore, transitional care systems that help ensure patients actually pick up and correctly start newly prescribed medications are likely to provide high value. 24 Medication initiation strategies should be complemented by efforts to limit potential burdens and side effects. These necessarily complex medication regimens, particularly for HFrEF and multi-morbidity, demand multifaceted disease-management solutions that are yet-to-be perfected. 25 The study has several limitations. Hospitals voluntarily participating fully in GWTG-HF may not be representative of hospitals or HF patients in the United States; however, prior study has shown that patients in GWTG-HF are relatively similar to cross-sectional samples of national HF hospitalizations. 10 Data were collected by chart review and so depend on the accuracy and completeness of documentation, particularly in terms of contraindications and intolerance.
GWTG-HF collects data by site and hospitalization event, not by unique patients, such that the effect of recurrent hospitalizations for individual patients is not specifically accounted for in this analysis. Laboratory values are optional fields in GWTG-HF with a high rate of missingness, to an extent that we decided not to impute laboratory values or confine the analysis to patients with ransitional care systems that help ensure patients actually pick up and correctly s s sta ta tart rt rt n n new ew ewly ly ly prescribed medications are likely to provide high value. 24 Medication initiation strategies should be c com om ompl pl plem em emen e e te e ed d d by b b efforts to limit potential bu u urd rd rde e ens and side effects. Th Th These necessarily c co com mp m lex medi d ca ca cat tio on n r r reg eg egim im imen en ens, s, s, p par ar arti ti ticu cu cula larly fo f f r r r HF FrE E EF a a and nd nd m m mul ul u ti ti ti-m -m mor orbi bi bid di dity, de de dema ma mand nd nd m m mu u ulti ti tifa fa face c c t te t d di i ise se s a as ase-mana na nag geme me ment s s sol l lutio on ns ns th t t at t t a a are e e y y yet e -t t to-o-o-b be p p per r rfect ct cte e ed. 2 2 25 Th Th The e e st st stud d udy ha ha has s s se se seve e vera ra ral l l li li limi mi mita ta tati ti tion on ons s s. H H Hos os ospi pi pita ta tals ls ls vol ol olun n unta ta tari ri rily l ly p p par ar arti ti tici ci cipa pa pati ti ting ng ng f f ful l ully l ly i i in n n GW GW GWTG TG TG H H -HF F F complete laboratory values; however, sites were required to choose contraindications to medications from a menu of accepted reasons that included hyperkalemia and worsening renal function for ACEI/ARB and AldA, such that these variables do get incorporated into data capture. We do not have data on post-discharge adherence or outcomes that would have allowed for further investigation into the potential implications of multiple medication starts.
Additionally, this analysis does not account for non-HF medications, which may significantly alter the complexity of discharge medication changes as narrowly reported here.
Conclusions
Nearly half of patients hospitalized with HF need to start at least one new medication, with 24%
having indications for at least 2 medications and 14% for 3 or more medications, in order to comply with current HF guidelines and hospital quality measures. Systems for addressing medication initiation and managing polypharmacy are central to HF transitional care efforts. 
